Stryker Co. (NYSE:SYK) Receives $371.68 Consensus Price Target from Analysts

Shares of Stryker Co. (NYSE:SYK) have earned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $373.11.

Several research analysts recently commented on SYK shares. Stifel Nicolaus cut their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Barclays lifted their price objective on shares of Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. BTIG Research decreased their target price on shares of Stryker from $372.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Piper Sandler lifted their target price on shares of Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Finally, UBS Group boosted their price objective on shares of Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st.

Stryker Price Performance

Shares of NYSE SYK opened at $315.94 on Thursday. Stryker has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The stock has a market cap of $120.40 billion, a price-to-earnings ratio of 36.07, a PEG ratio of 2.56 and a beta of 0.89. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.99 and a current ratio of 1.68. The firm’s 50-day simple moving average is $338.87 and its 200 day simple moving average is $339.97.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.79 by $0.02. The firm had revenue of $5.42 billion during the quarter, compared to analyst estimates of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the business posted $2.54 EPS. As a group, research analysts anticipate that Stryker will post 11.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th were issued a dividend of $0.80 per share. The ex-dividend date was Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 1.01%. Stryker’s payout ratio is 36.53%.

Insider Activity

In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the sale, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Several institutional investors have recently bought and sold shares of SYK. Burkett Financial Services LLC bought a new stake in shares of Stryker in the 4th quarter worth about $25,000. Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in shares of Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the last quarter. Rogco LP bought a new stake in shares of Stryker in the 4th quarter worth about $30,000. DSM Capital Partners LLC bought a new stake in shares of Stryker in the 4th quarter worth about $34,000. Finally, HBC Financial Services PLLC bought a new stake in shares of Stryker in the 4th quarter worth about $37,000. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.